
Syros Pharmaceuticals
Syros Pharmaceuticals: A global biopharmaceutical firm specializing in gene control medicines for cancer and immune diseases.

Syros Pharmaceuticals: A global biopharmaceutical firm specializing in gene control medicines for cancer and immune diseases.
Syros Pharmaceuticals, founded with a mission to revolutionize the treatment of cancer and immune-mediated diseases, focuses on the development of gene control medicines. The company leverages its expertise in gene regulatory circuits to identify and target aberrant gene expressions in cells, aiming to create new therapeutic standards for patients, particularly in hematologic malignancies. Syros operates globally, striving to bring innovative treatments to the forefront of medical care.
Notable figures associated with Syros Pharmaceuticals include its co-founders and leading scientists in gene regulation. The company has attracted significant investment from prominent venture capital firms and strategic partners in the biopharmaceutical industry. Key achievements include the advancement of multiple drug candidates into clinical trials and the establishment of a robust pipeline of potential therapies. Syros's impact lies in its pioneering approach to gene control, offering hope for more effective treatments for complex diseases.
Companies similar to Syros Pharmaceuticals include Rheos Medicines, SynerGene Therapeutics, Fulcrum Therapeutics and Syndax Pharmaceuticals.
Syros Pharmaceuticals was founded in 2011.
Syros Pharmaceuticals' headquarters is located in Cambridge, MA, US.
Syros Pharmaceuticals' most recent funding round was for $45M (USD) in December 2023.
As of Dec 19, 2023, Syros Pharmaceuticals has disclosed funding of $620.5M (USD). Undisclosed round amounts are excluded.
Syros Pharmaceuticals has 117 employees as of Feb 6, 2024.

Syndax Pharmaceuticals
syndax.com